GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)

NCT ID: NCT04196413

Last Updated: 2025-12-17

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 97 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-06-04
• Study Completion Date: 2043-07-31

Brief Summary

The primary purpose of this study is to test whether CAR T cells targeting GD2 (GD2CART) can be successfully made and safely given to children and adults with H3K27M-mutant diffuse midline glioma (DMG). Eligible subjects may have DMG arising in the pons (called difuse intrinisic pontine glioma, DIPG), the spinal cord, or other areas of the brain such as a thalamus

Detailed Description

Primary Objectives:

• Determine the feasibility of manufacturing autologous T cells transduced with 14g2a-CD8-BBz-iCasp9 retroviral vector expressing GD2 Chimeric Antigen Receptor (GD2CART) for administration in subjects with H3K27M-mutant diffuse midline glioma (DMG) using a retroviral vector and dasatinib in the Miltenyi CliniMACS Prodigy® system.
• Assess the safety and identify the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), route and schedule of GD2CART and lymphodepleting chemotherapy in subjects with H3K27M-mutant DMG.
• Assess the safety of the MTD/RP2D, route and schedule of GD2CART in expansion cohorts of subjects with H3K27M-mutant DMG.

Secondary Objectives:

• In a preliminary manner, assess clinical benefit and Patient Reported Outcomes (PROs) of GD2CART at the RP2D in children and adults with H3K27M-mutant DMG.
• Evaluate the safety and impact on clinical benefit of repeat intracerebroventricular (ICV) administrations of GD2CART according to Arms A, B, C or D.
• If unacceptable toxicity occurs that is possibly, probably or likely related to GD2CART, assess the capacity for AP1903, a dimerizing agent, to mediate clearance of the genetically engineered cells and resolve toxicity.

Conditions

Glioma of Spinal Cord; Glioma of Brainstem

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ARM A

GD2CART will be administered on Day 0 in hospitalized subjects with either DIPG or spinal DMG

Intravenously, after conditioning lymphodepletion chemotherapy regimen with cyclophosphamide and fludarabine

• Dose Level -1: 3x10^5 transduced T cells/kg(± 20%)
• Dose Level 1: 1x10^6 transduced T cells/kg (± 20%)
• Dose Level 2: 3x10^6 transduced T cells/kg (± 20%)

Group Type: EXPERIMENTAL

GD2 CAR T cells

Intervention Type: DRUG

Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor

Fludarabine

Intervention Type: DRUG

Fludarabine 30 mg/m2 per day IV for days -4, -3, -2

Cyclophosphamide

Intervention Type: DRUG

Cyclophosphamide 500 mg/m2 per day IV for days -4, -3, -2

ARM B

GD2CART will be administered on Day 0 in hospitalized subjects with either DIPG or spinal DMG

Intracerebroventricularly, without conditioning lymphodepletion chemotherapy

• Dose Level -1: 10x10^6 transduced T cells (±20%)
• Dose Level 1: 30x10^6 transduced T cells (±20%)
• Dose Level 2: 50x10^6 transduced T cells (±20%)
• Dose Level 3: 100x10^6 transduced T cells (±20%)

Group Type: EXPERIMENTAL

GD2 CAR T cells

Intervention Type: DRUG

Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor

ARM C

GD2CART will be administered in escalating doses on Day 0 in hospitalized subjects with either DIPG or spinal DMG

Intracerebroventricularly after administration of conditioning lymphodepletion chemotherapy regimen with cyclophosphamide and fludarabine

• Dose Level -1: 10x10^6 transduced T cells (±20%)
• Dose Level 1: 30x10^6 transduced T cells (±20%)
• Dose Level 2: 50x10^6 transduced T cells (±20%)

Group Type: EXPERIMENTAL

GD2 CAR T cells

Intervention Type: DRUG

Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor

Fludarabine

Intervention Type: DRUG

Fludarabine 30 mg/m2 per day IV for days -4, -3, -2

Cyclophosphamide

Intervention Type: DRUG

Cyclophosphamide 500 mg/m2 per day IV for days -4, -3, -2

ARM D

GD2CART will be administered in escalating doses on Day 0 in hospitalized subjects with either DIPG, spinal DMG, or high risk features.

Intracerebroventricularly after administration of conditioning lymphodepletion chemotherapy regimen with rituximab, cyclophosphamide and fludarabine

• Dose Level -1: 10x10^6 transduced T cells (±20%)
• Dose Level 1: 30x10^6 transduced T cells (±20%)
• Dose Level 2: 50x10^6 transduced T cells (±20%)

Group Type: EXPERIMENTAL

GD2 CAR T cells

Intervention Type: DRUG

Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor

Fludarabine

Intervention Type: DRUG

Fludarabine 30 mg/m2 per day IV for days -4, -3, -2

Cyclophosphamide

Intervention Type: DRUG

Cyclophosphamide 500 mg/m2 per day IV for days -4, -3, -2

Rituximab

Intervention Type: DRUG

First round: 750 mg/m2 per day IV for days -6 and -5. Subsequent rounds: 750 mg/m2 per day IV for day -5.

Interventions

GD2 CAR T cells

Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor

Intervention Type: DRUG

Fludarabine

Fludarabine 30 mg/m2 per day IV for days -4, -3, -2

Intervention Type: DRUG

Cyclophosphamide

Cyclophosphamide 500 mg/m2 per day IV for days -4, -3, -2

Intervention Type: DRUG

Rituximab

First round: 750 mg/m2 per day IV for days -6 and -5. Subsequent rounds: 750 mg/m2 per day IV for day -5.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Disease Status: Diagnosis of H3K27M mutant diffuse midline glioma (DMG)

2. H3K27M or H3K27I mutation. Confirmed by CLIA test.

3. Age: Greater than or equal to 2 year of age and less than or equal to 60 years of age.

4. Prior Therapy:

• At least 4 weeks following completion of standard upfront radiation therapy.
• At least 3 weeks post chemotherapy or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy, except for systemic inhibitory/stimulatory immune checkpoint therapy that requires 3 months.
• Dordaviprone (Modeyso), previously known as ONC201, may be taken as prior therapy but - just as with other anti-cancer medications - administration must cease at least 5 half-lives prior to enrollment

5. Performance Status:

Subjects > 16 years of age: Karnofsky ≥ 60% OR Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Subjects ≤ 16 years of age: Lansky scale ≥ 60%.

Subjects who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

6. Normal Organ and Marrow Function (supportive care is allowed per institutional standards, i.e. filgrastim, transfusion) i. ANC ≥ 1000/uL ii. Platelet count ≥ 100,000/uL iii. Absolute lymphocyte count ≥ 150/uL iv. Hemoglobin ≥ 8 g/dL v. Adequate renal, hepatic, pulmonary and cardiac function defined as:

• Creatinine within institutional norms for age (i.e.

≤ 2 mg/dL in adults or according to table below in children <18 years) OR creatinine clearance (as estimated by Cockcroft Gault Equation) ≥ 60 mL/min

Serum ALT/AST ≤ 3.0 ULN (grade 1)

• Total bilirubin ≤ 1.5 mg/dl, except in subjects with Gilbert's syndrome.
• Cardiac ejection fraction ≥ 45%, no evidence of physiologically significant pericardial effusion as determined by an ECHO, and no clinically significant ECG findings
• Baseline oxygen saturation > 92% on room air

7. Pregnancy Test Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization are not considered to be of childbearing potential) or NA

8. Contraception Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four (4) months after receiving the preparative regimen or for as long as GD2CART cells are detectable in peripheral blood or CSF.

9. Ability to give informed consent. All subjects ≥ 18 years of age must be able to give informed consent. For subjects <18 years old their legal authorized representative (LAR) (i.e. parent or guardian) must give informed consent. Pediatric subjects will be included in age appropriate discussion and written assent will be obtained for those > 7 years of age, when appropriate. If a minor becomes of age during participation of this study, he/she will be asked to reconsent as an adult.

Exclusion Criteria

1. For Dose Escalation: Bulky tumor involvement of cerebellar vermis or hemispheres (pontocerebellar peduncles involvement is acceptable), or thalamic lesions that in the investigator's assessment place the subject at unacceptable risk for herniation.

For Dose Expansion: Bulky disease that in the investigator's assessment place the subject at unacceptable risk for herniation. Thalamic DMG is permitted.

2. Clinically significant swallowing dysfunction/dysphagia or prominent medullary dysfunction, as determined by the clinical investigator; or primary cervical cord tumors above C6/7 that represent a high risk of respiratory compromise, as determined by the clinical investigator.

3. Current systemic corticosteroid therapy above physiologic replacement levels.

4. Ongoing use of dietary supplements, alternative therapies or extreme diet modifications or any medication not approved by the investigators

5. Prior CAR therapy.

6. Prior immunomodulatory therapy, except for checkpoint inhibitor therapy after at least 3 month wash-out.

7. Uncontrolled fungal, bacterial, viral, or other infection. Previously diagnosed infection for which the patient continues to receive antimicrobial therapy is permitted if responding to treatment and clinically stable.

8. Diagnosed ongoing infection with:

• HIV,
• Hepatitis B (HBsAg positive) or
• Hepatitis C virus (anti-HCV positive). A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and/or nucleic acid testing.

9. Clinically significant systemic illness or medical condition (e.g. significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the judgement of the principal investigator is likely to interfere with assessment of safety or efficacy of the investigational regimen and its requirements.

10. Women who are pregnant or breastfeeding.

11. In the investigator's judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.

12. Known sensitivity or allergy to any agents/reagents used in this study.

13. Primary immunodeficiency or history of autoimmune disease (e.g. Crohns, rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years

• All subject files must include supporting documentation to confirm subject eligibility.

The method of confirmation can include, but is not limited to, laboratory test results, radiology test results, subject self-report, and medical record review.

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

California Institute for Regenerative Medicine (CIRM)

OTHER

Sponsor Role: collaborator

CureSearch

UNKNOWN

Sponsor Role: collaborator

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Alex's Lemonade Stand Foundation (ALSF)

UNKNOWN

Sponsor Role: collaborator

Parker Institute for Cancer Immunotherapy

OTHER

Sponsor Role: collaborator

Stanford University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michelle Monje

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Locations

Lucile Packard Children's Hospital (LPCH)

Stanford, California, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Ashley Jacobs, RN, BSN

Role: CONTACT

gd2cart@stanfordchildrens.org

650-497-7533

Monica Reddy

Role: CONTACT

secure-gd2cart-adult@lists.stanford.edu

(650) 736-2690

Facility Contacts

Ashley Jacobs

Role: primary

GD2CART@stanfordchildrens.org

650-497-7533

Monica Reddy

Role: backup

secure-gd2cart-adult@lists.stanford.edu

(650) 736-2690

Other Identifiers

PEDSCCT6005

Identifier Type: OTHER

Identifier Source: secondary_id

NCI-2020-05891

Identifier Type: OTHER

Identifier Source: secondary_id

5R01CA263500-05

Identifier Type: NIH

Identifier Source: secondary_id

View Link

IRB-52934

Identifier Type: -

Identifier Source: org_study_id